Detalhe da pesquisa
1.
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.
Cell
; 185(22): 4216-4232.e16, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240780
2.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Hepatology
; 77(1): 20-32, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35686937
3.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Gut
; 72(3): 581-589, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750244
4.
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
J Lipid Res
; 64(3): 100339, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737040
5.
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
J Hepatol
; 78(2): 247-259, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375686
6.
The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Clin Gastroenterol Hepatol
; 21(4): 970-977.e1, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35533993
7.
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Clin Gastroenterol Hepatol
; 21(1): 143-152.e3, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999207
8.
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Clin Gastroenterol Hepatol
; 21(1): 90-102.e6, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074532
9.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934287
10.
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Hepatology
; 75(5): 1235-1246, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34662449
11.
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Hepatology
; 76(6): 1811-1824, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35561146
12.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
BMC Gastroenterol
; 23(1): 75, 2023 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922785
13.
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
J Lipid Res
; 63(9): 100250, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835205
14.
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
J Hepatol
; 77(3): 607-618, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439567
15.
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Gastroenterology
; 160(5): 1608-1619.e13, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33307033
16.
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hepatology
; 74(6): 3146-3160, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333790
17.
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Hepatology
; 73(3): 1105-1116, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745270
18.
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
Hepatology
; 74(1): 133-147, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570776
19.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Hepatology
; 73(2): 625-643, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169409
20.
Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance.
AJR Am J Roentgenol
; 219(2): 224-232, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35107306